TAIKO PHARMACEUTICAL CO.,LTD. [4574.T]
TOKYO, May 14 (Pulse News Wire) – Taiko Pharmaceutical CO.,LTD. (4574.T) reported a lower net profit of ¥95 million for the quarter ending March 31, 2026, compared to a profit of ¥292 million in the same period last year.
The company's revenue was ¥916 million, down from ¥1.150 billion in the previous year due to lower sales volumes across its pharmaceutical and infection management segments. In the pharmaceutical sector, domestic sales declined by 28.6%, while overseas sales increased slightly. However, overall revenue decreased by 20%. The company attributed the decline to supply issues affecting products such as Seirogan tablets and competitive pressures from rival companies.
For the infection management division, revenue dropped by 64.4% amid reduced demand and cost-cutting measures. Despite efforts to improve profitability through cost control, the segment continued to incur losses. Looking ahead, Taiho Pharmaceutical maintained its annual forecast, expecting total revenue of ¥1.043 billion for the fiscal year ending December 2026, with operating income and net income yet to be determined. The company noted ongoing uncertainties related to geopolitical tensions and rising material costs but stated there would be no changes to its previously disclosed projections.
Financial results — FY2026/12 (consolidated)
| Metric | Current | YoY |
|---|---|---|
| Revenue | ¥916M | -20.4% |
| Operating profit | ¥-98M | n/a |
| Net profit | ¥-95M | n/a |
Next period forecast
Revenue
¥7,200M
+12.5%Op. profit
¥500M
+8.9%Net profit
¥550M
-40.4%Source: TDNet filing · Figures in millions of yen
🟢 Confidence: High AI-translated content.